Adverse Events Module

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module

Ignite Creation Date: 2025-12-24 @ 3:20 PM
Ignite Modification Date: 2025-12-25 @ 1:40 PM
NCT ID: NCT04229992
Description: The definition of adverse event and/or serious adverse event is from the clinicaltrials.gov Definitions. We conducted safety and compliance calls to collect adverse event data.
Frequency Threshold: 0
Time Frame: In the 12 weeks trial, we conducted safety and compliance calls to collect adverse event data.
Study: NCT04229992
Study Brief: Calcium: Magnesium Balance, Microbiota, and Necroptosis and Inflammation
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
GA/AA Genotype and Magnesium Treatment Participants who have the GA/AA genotype were assigned to magnesium glycinate Magnesium glycinate: Oral administration of magnesium glycinate daily for 12 weeks 0 None 0 47 3 47 View
GA/AA Genotype and Placebo Participants who have the GA/AA genotype were assigned to placebo group Placebo: Oral administration of identical-appearing placebo daily for 12 weeks 0 None 0 48 1 48 View
GG Genotype and Magnesium Treatment Participants who have the GG genotype were assigned to magnesium glycinate Magnesium glycinate: Oral administration of magnesium glycinate daily for 12 weeks 0 None 0 77 1 77 View
GG Genotype and Placebo Participants who have the GG genotype were assigned to placebo group Placebo: Oral administration of identical-appearing placebo daily for 12 weeks 0 None 0 78 2 78 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Feel sick SYSTEMATIC_ASSESSMENT General disorders None View
Having an adverse effect on his blood pressure medication SYSTEMATIC_ASSESSMENT General disorders None View
Weight gain, migraine and swelling with arthritic pain in fingers SYSTEMATIC_ASSESSMENT General disorders None View
Bleeding after the rectal biopsy procedure SYSTEMATIC_ASSESSMENT Gastrointestinal disorders None View
abdominal pain SYSTEMATIC_ASSESSMENT Gastrointestinal disorders None View